Nicholas Hoffman & Company LLC. Invests $472,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Nicholas Hoffman & Company LLC. bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 763 shares of the medical research company’s stock, valued at approximately $472,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Willis Johnson & Associates Inc. acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at $206,000. Veracity Capital LLC increased its stake in shares of Thermo Fisher Scientific by 20.0% in the 1st quarter. Veracity Capital LLC now owns 737 shares of the medical research company’s stock valued at $428,000 after buying an additional 123 shares during the period. J.W. Cole Advisors Inc. increased its stake in shares of Thermo Fisher Scientific by 76.3% in the 1st quarter. J.W. Cole Advisors Inc. now owns 3,953 shares of the medical research company’s stock valued at $2,297,000 after buying an additional 1,711 shares during the period. SeaBridge Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 7.0% in the 1st quarter. SeaBridge Investment Advisors LLC now owns 11,207 shares of the medical research company’s stock valued at $6,514,000 after buying an additional 730 shares during the period. Finally, Diversify Advisory Services LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at $3,206,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,300 shares of company stock worth $6,831,268 over the last three months. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.5 %

Shares of NYSE:TMO opened at $550.43 on Thursday. Thermo Fisher Scientific Inc. has a 12-month low of $433.15 and a 12-month high of $627.88. The stock has a market cap of $210.26 billion, a PE ratio of 34.51, a P/E/G ratio of 3.66 and a beta of 0.77. The business has a 50 day moving average of $601.50 and a 200-day moving average of $583.56. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.69 earnings per share. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Stifel Nicolaus reduced their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Bernstein Bank lifted their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Raymond James lifted their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, Barclays reduced their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.